Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Thyroid Nodule 1Social Isolation 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neurobehavioral Manifestations 1Lung Neoplasms 1Disease 1Depression 1Communication 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Central Nervous System Neoplasms 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

Carboplatin 339Cisplatin 238Paclitaxel 203Radiotherapy 194Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 140Erlotinib Hydrochloride 107Etoposide 98Magnetic Resonance Spectroscopy 92Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 71durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49Irinotecan 42atezolizumab 41Topotecan 39Radiation 39Biopsy 39Cyclophosphamide 38Standard of Care 37Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × Artificial Intelligence × Clear all
NCT07458425 2026-04-06

The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk

University of Illinois at Chicago

Phase NA Recruiting
400 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡